menu
    • menu
    [{"orgOrder":0,"company":"VISUfarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"VISUfarma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VISUfarma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"VISUfarma \/ Undisclosed"},{"orgOrder":0,"company":"VISUfarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Coqun","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"VISUfarma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VISUfarma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VISUfarma \/ Undisclosed"},{"orgOrder":0,"company":"VISUfarma","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"VISUfarma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VISUfarma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"VISUfarma \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by VISUfarma

    Menu

    VISUfarma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Ectoine,Fucoidan

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin Strengthens its Ophthalmology Business with Acquisition of VISUfarma

                            Details : The acquisition of VISUfarma, with its broad portfolio of innovative eye health products, including Xailin Ectoine, aligns with Lupin's strategy to expand its European business.

                            Product Name : Xailin Ectoine

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 29, 2025

                            Lead Product(s) : Hyaluronic Acid,Ectoine,Fucoidan

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients A...

                            Details : CoQ10 is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 30, 2019

                            Lead Product(s) : Coenzyme Q10

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coqun

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Study of COQUN ORAL FORMULATION

                            Details : Coqun is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 28, 2019

                            Lead Product(s) : Coqun

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth